Despite zero revenue and increased losses, Capricor Therapeutics Inc (CAPR) focuses on strategic initiatives and regulatory ...

Cambridge-based Sarepta Therapeutics Inc. stock dropped 1.6 percent in Monday trading. Capricor Therapeutics Inc. fell 13.8 percent and Replimune Group Inc. was down 5.7 percent. Prasad left the ...

Type A meeting with U.S. FDA scheduled to discuss Deramiocel BLA and path toward potential approvalCapricor seeks to resubmit ...

Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping ...

Detailed price information for Capricor Therap (CAPR-Q) from The Globe and Mail including charting and trades.

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration.

Shares of C3.ai, Inc. AI -31.3% Get Free Report fell sharply in pre-market trading after the company reported preliminary ...

At 05:45 a.m. ET, Dow E-minis were up 98 points, or 0.22%, with 7,922 contracts changing hands, S&P 500 E-minis were up 6.25 ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration ...

Shares of International Money Express, Inc. IMXI +56.3% Get Free Report rose sharply in pre-market trading after Western ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, b ...

One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the ...